Business · 09/09/2026

FDA Determines Regulatory Review Period for ANKTIVA Patent Extension

The U.S. Food and Drug Administration (FDA) has published a notice determining the regulatory review period for ANKTIVA, a human biological product, in response to a patent extension application submitted to the U.S. Patent and Trademark Office (USPTO).